<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02330484</url>
  </required_header>
  <id_info>
    <org_study_id>CCEMD-026</org_study_id>
    <nct_id>NCT02330484</nct_id>
  </id_info>
  <brief_title>Affect of Incentive Strategy on the Adherence to Medication Among Patients With Type 2 Diabetes</brief_title>
  <official_title>Affect of Incentive Strategy on the Adherence to Medication Among Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on patients' HbA1c improvement, this study aims to establish an incentive strategy to
      family physicians and patients respectively to evaluate the affect on the adherence to
      medication among patients with type2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First step: In this study, the investigators will conduct an open-label controlled randomized
      cluster trial to enroll 400 eligible and voluntary patients with type 2 diabetes from the
      community. 16 physicians will be involved in this study for patient management. Each
      physician will care at least 20 patients as a random unit which will be divided into 4 groups
      for baseline assessment including demographic characteristics, diabetes diagnosis and
      treatment, complication, biochemical indexes and self-management. The involved patients and
      physicians will receive related training. The patients will sign the informed consent form.

      Second step: This study aims to give incentives to physicians or patients or both the
      physicians and patients based on HbA1c improvement. All the patients will sign the informed
      consent form. Regarding to the control group, health courses and community management will be
      given as usual. the investigators will evaluate the condition of patients' medication
      adherence after giving the incentives.

      Third step: MEMS will be used in the intervention to monitoring patients' medication
      adherence. As a monitoring instrument, MEMS (Aardex, Zurich, Switzerland) is a plastic
      container with a spring-loaded device in the cap. Each time the bottles is opened for at
      least 3 seconds, the time and date of opening are recorded and saved. Based on the research
      data and the HbA1c improvement, this study will analyze the other factors which affect the
      patients' adherence to medication. Meanwhile, the investigators will collect patients'
      information such as blood pressure, biochemical index, complications related to diabetes,
      life quality, self-management, life style, health behavior, medications, health expenditure
      so as to evaluate the affect of incentive strategy on the adherence to medication among
      patients with type 2 diabetes.

      Endpoint of the study:

      The study will be ended in 12 months, endpoint measurement indicators are listed below:

        1. The study will be ended in 12 months

        2. Patient's drop out of the study

        3. Stopping taking oral hypoglycemic drugs

        4. The diabetic condition worsen, needs surgery or hospitalization treatment

        5. Frequency of severe hypoglycemia or other complications that can not continue the study

        6. Death of the patient
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypoglycemic Medication adherence rates using electronically monitored adherence (MEMS cap) data</measure>
    <time_frame>12 months</time_frame>
    <description>MEMS will be used in the intervention to monitoring patients' medication adherence. As a monitoring instrument, MEMS (Aardex, Zurich, Switzerland) is a plastic container with a spring-loaded device in the cap. Each time the bottles is opened for at least 3 seconds, the time and date of opening are recorded and saved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-report medication adherence</measure>
    <time_frame>12 months</time_frame>
    <description>The investigators assess adherence with MMAS 8-item version and BMQ-specific.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of HbA1c</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on the Diabetes Quality Of Life</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEMS cap data compared to PHQ-9 and AIS assessment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>incentives to physicians</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give incentives to physicians according to patients' HbA1c improvement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>incentives to patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give incentives to patients according to their HbA1c improvement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>incentives to both physicians and patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention mode: Give incentives to physicians and patients according to patients' HbA1c improvement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group with no incentives</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Give incentives to patients based on their own HbA1c improvement</intervention_name>
    <description>Give incentives to patients based on their own HbA1c improvement</description>
    <arm_group_label>incentives to patients</arm_group_label>
    <arm_group_label>incentives to both physicians and patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Give incentives to physician based on their patient's HbA1c improvement</intervention_name>
    <description>Give incentives to physician based on their patient's HbA1c improvement</description>
    <arm_group_label>incentives to physicians</arm_group_label>
    <arm_group_label>incentives to both physicians and patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed type 2 diabetes patients (ICD9) according to the medical record and
             patient's disease history

          2. 40 to 74 years old

          3. Diagnosis type 2 diabetes more than 6 months

          4. Take at least one kind of oral hypoglycemic medication(including insulin injection)

          5. Got treatment in community hospitals or follow up for more than 12 months

          6. Have medical insurance

          7. Stable condition with no adverse indication

          8. Participate in this study voluntarily and sign the inform consent from

        Exclusion Criteria:

          1. Terminal illness

          2. Serious hearing and visual disorder

          3. Intend to receive selective surgery, to get pregnancy and breast feeding in three
             months

          4. Demnentia or communication disorders

          5. Mental disorders

          6. The paralyzed or the handicapped

          7. Expected survival time less than one-year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liebin Zhao, MSM</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Clinical Centre for Endocrinology and Metabolism</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin hospital, Shanghai Jiao-Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2014</study_first_submitted>
  <study_first_submitted_qc>December 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2015</study_first_posted>
  <last_update_submitted>December 31, 2014</last_update_submitted>
  <last_update_submitted_qc>December 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Guang Ning</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Community managementï¼Œ incentives, Medication Adherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

